MedTrace Logo

Pasireotide LAR and Pegvisomant Study in Acromegaly

NCT02668172 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2016-08-03

No results posted yet for this study

Summary

The objective of this study is to assess the efficacy of Pasireotide Long Acting Release (LAR) alone and in combination with weekly Pegvisomant (PEGV) in acromegaIy patients previously controlled with combination treatment of long-acting Somatostatin analogs (LA-SSAs) and PEGV.

Conditions

Interventions

DRUG

Pasireotide LAR 60 mg

as mono-therapy or in combination with pegvisomant

DRUG

Pegvisomant

only in combination with pasireotide LAR

Sponsors & Collaborators

Principal Investigators

  • Sebastian Neggers, MD PhD · Erasmus Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2017-03-31
Completion
2017-06-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02668172 on ClinicalTrials.gov